Ioxilan
![]() | |
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
Pregnancy category |
|
Routes of administration | intravenously |
ATC code | V08AB12 (WHO) |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | N/A |
Protein binding | negligible |
Biological half-life | 2 hours |
Excretion | Mostly renal |
Identifiers | |
| |
CAS Number |
107793-72-6 ![]() |
PubChem (CID) | 3743 |
ChemSpider |
3612 ![]() |
UNII |
A4YJ7J11TG ![]() |
KEGG |
D02161 ![]() |
ChEMBL |
CHEMBL1201075 ![]() |
Chemical and physical data | |
Formula | C18H24I3N3O8 |
Molar mass | 791.112 |
3D model (Jmol) | Interactive image |
| |
| |
![]() ![]() |
Ioxilan is a diagnostic contrast agent. It is injected intravenously before taking X-ray images to increase arterial contrast in the final image. It is marketed under the trade name Oxilan by Guerbet, L.L.C.
This article is issued from Wikipedia - version of the 4/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.